X‐linked lymphoproliferative syndrome associated with Epstein–Barr virus encephalitis and lymphoproliferative disorder
Key Clinical Message When treating patients with EBV encephalitis, the possibility of XLP should be considered. Once the diagnosis of XLP is made, aggressive treatment such as rituximab, and other immunosuppressive agents are desired for rapid transition to HSCT.
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-09-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.7949 |
| _version_ | 1827788788755070976 |
|---|---|
| author | Takeo Mukai Kenji Waki |
| author_facet | Takeo Mukai Kenji Waki |
| author_sort | Takeo Mukai |
| collection | DOAJ |
| description | Key Clinical Message When treating patients with EBV encephalitis, the possibility of XLP should be considered. Once the diagnosis of XLP is made, aggressive treatment such as rituximab, and other immunosuppressive agents are desired for rapid transition to HSCT. |
| first_indexed | 2024-03-11T17:10:30Z |
| format | Article |
| id | doaj.art-8ac16d10632f4a22ba09be3fc3fad453 |
| institution | Directory Open Access Journal |
| issn | 2050-0904 |
| language | English |
| last_indexed | 2024-03-11T17:10:30Z |
| publishDate | 2023-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical Case Reports |
| spelling | doaj.art-8ac16d10632f4a22ba09be3fc3fad4532023-10-20T06:16:22ZengWileyClinical Case Reports2050-09042023-09-01119n/an/a10.1002/ccr3.7949X‐linked lymphoproliferative syndrome associated with Epstein–Barr virus encephalitis and lymphoproliferative disorderTakeo Mukai0Kenji Waki1Department of Pediatrics The University of Tokyo Hospital Tokyo JapanDepartment of Pediatrics Kurashiki Central Hospital Okayama JapanKey Clinical Message When treating patients with EBV encephalitis, the possibility of XLP should be considered. Once the diagnosis of XLP is made, aggressive treatment such as rituximab, and other immunosuppressive agents are desired for rapid transition to HSCT.https://doi.org/10.1002/ccr3.7949Epstein–Barr virushemophagocytic Lymphohistiocytosislymphoproliferative disordersrituximabX‐linked lymphoproliferative syndrome |
| spellingShingle | Takeo Mukai Kenji Waki X‐linked lymphoproliferative syndrome associated with Epstein–Barr virus encephalitis and lymphoproliferative disorder Clinical Case Reports Epstein–Barr virus hemophagocytic Lymphohistiocytosis lymphoproliferative disorders rituximab X‐linked lymphoproliferative syndrome |
| title | X‐linked lymphoproliferative syndrome associated with Epstein–Barr virus encephalitis and lymphoproliferative disorder |
| title_full | X‐linked lymphoproliferative syndrome associated with Epstein–Barr virus encephalitis and lymphoproliferative disorder |
| title_fullStr | X‐linked lymphoproliferative syndrome associated with Epstein–Barr virus encephalitis and lymphoproliferative disorder |
| title_full_unstemmed | X‐linked lymphoproliferative syndrome associated with Epstein–Barr virus encephalitis and lymphoproliferative disorder |
| title_short | X‐linked lymphoproliferative syndrome associated with Epstein–Barr virus encephalitis and lymphoproliferative disorder |
| title_sort | x linked lymphoproliferative syndrome associated with epstein barr virus encephalitis and lymphoproliferative disorder |
| topic | Epstein–Barr virus hemophagocytic Lymphohistiocytosis lymphoproliferative disorders rituximab X‐linked lymphoproliferative syndrome |
| url | https://doi.org/10.1002/ccr3.7949 |
| work_keys_str_mv | AT takeomukai xlinkedlymphoproliferativesyndromeassociatedwithepsteinbarrvirusencephalitisandlymphoproliferativedisorder AT kenjiwaki xlinkedlymphoproliferativesyndromeassociatedwithepsteinbarrvirusencephalitisandlymphoproliferativedisorder |